Klin Farmakol Farm. 2011;25(2):59-63

Safety of antiepileptic drugs and it´s relation to the quality of life in paediatric patients with epilepsy

Ľubomír Virág1,2, Miroslav Murgaš3, Magdaléna Kuželová1
1 Katedra farmakológie a toxikológie, Farmaceutická fakulta, Univerzita Komenského v Bratislave, Slovenská republika
2 Lekáreň a Čajka, Nitra, Slovenská republika
3 Detská neurologická ambulancia, Nitra, Slovenská republika

Purpose: To analyse safety of antiepileptic drugs (AEDs) and its impact on quality of life in paediatric outpatients with epilepsy.

Methods: The present study was a retrospective survey conducted at the Outpatient Department of Paediatric Neurology in Nitra, Slovakia.

The study population comprised 293 patients (148 girls and 145 boys; a mean age of 10.9). The data were collected retrospectively

from patient´s medical record. All adverse effects (AEs) were characterised with respect to their probability and severity. QOLIE-AD-48

questionnaire was used to assess quality of life prospectively (10/2005–01/2009). Chi-square test was conducted to compare discrete

variables. p < 0.05 was considered significant.

Results: Adverse effects of the AEDs were presented at 32.8 % of the patients. The most of AEs occurred in patients medicated with

classical AEDs (valproic acid, carbamazepine; classical vs new AEDs, p < 0.01). The most common (40.6 %) were central nervous system

disorders (fatigue, tremor, headache, diplopia). The most of AEs were judged to be AED related – 55.6 % probably and 39.1 % possibly.

Eleven (8.3 %) AEs were judged to be serious. Questionnaires were returned by 74 (77.9 %) paediatric patients. The mean quality of life

score was 75.2. The quality of life score was lower in children who were medicated by polytherapy (monotherapy vs polytherapy, p < 0.05),

and also in those who experienced AEs (AEs vs no AEs, p < 0.01).

Conclusion: Adverse effects of antiepileptic drugs were presented relatively often and had negative impact on quality of life in children

with epilepsy.

Keywords: antiepileptic drugs, paediatric patients, quality of life, adverse effects

Published: June 20, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Virág Ľ, Murgaš M, Kuželová M. Safety of antiepileptic drugs and it´s relation to the quality of life in paediatric patients with epilepsy. Klin Farmakol Farm. 2011;25(2):59-63.
Download citation

References

  1. Perucca E, Beghi E, Dulac O. Assesing risk to benefit ratio in antiepileptic drug therapy. Epilepsy Res 2000; 41: 107-139. Go to original source... Go to PubMed...
  2. Gilliam FG, Carter J, Vahle V. Tolerability of antiseizure medications: implications for health outcomes. Neurology 2004; 63: 9-12. Go to original source... Go to PubMed...
  3. Mattson RH. Monotherapy trials: endpoints. Epilepsy Res 2001; 45: 109-117. Go to original source... Go to PubMed...
  4. Gilliam FG, Fessler AJ, Baker G, Vahle V, Carter J, Attarian H. Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology 2004; 62: 23-27. Go to original source... Go to PubMed...
  5. Devinsky O, Cramer J. Safety and efficacy of standard and new antiepileptic drugs. Neurology 2000; 55: 5-10. Go to PubMed...
  6. French JA. The role of new antiepileptic drugs. Am J Manag Care 2001; 7: 209-214.
  7. Fayers PM, Machin D. Quality of life. The assessment, analysis and interpretation of patient-reported outcomes. 2nd ed. Chichester, John Wiley and Sons, 2007: 544.
  8. Jacoby A, Baker GA. Quality of life trajectories in epilepsy: a review of the literature. Epilepsy Behav 2008; 12: 557-571. Go to original source... Go to PubMed...
  9. Berto P. Quality of life in patients with epilepsy and impact of treatments. Pharmacoeconomics 2002; 20: 1039-1059. Go to original source... Go to PubMed...
  10. Senol V, Soyuer F, Arman F, Ozturk A. Influence of fatigue, depression, demographic, socioeconomic and clinical variables on quality of life of patients with epilepsy. Epilepsy Behav 2007; 10: 96-104. Go to original source... Go to PubMed...
  11. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domeq C, Greenblatt J. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245. Go to original source... Go to PubMed...
  12. Neubert A, Dormann H, Weiss J, Criegee-Rieck M, Ackermann A, Levy M, Brune K, Rascher W. Are computerised monitoring systems of value to improve pharmacovigilance in paediatric patients? Eur J Clin Pharmacol 2006; 62: 959-965. Go to original source... Go to PubMed...
  13. Cramer JA, Westbrook LE, Devinsky O, Perrine K, Glassman MB, Camfield C. Development of the quality of life in epilepsy inventory for adolescents: the QOLIE -AD - 48. Epilepsia 1999; 8: 1114-1121. Go to original source... Go to PubMed...
  14. Glauser TA, Sankar R. Core elements of epilepsy diagnosis and management: expert consensus. Curr Med Res Opin 2008; 24: 3463-3477. Go to original source... Go to PubMed...
  15. Kothare SV, Kaleyias J. The adverse effects of antiepileptic drugs in children. Expert Opin Drug Saf 2007; 6: 251-265. Go to original source... Go to PubMed...
  16. Walia KS, Khan EA, Ko DH, Raza SS, Khan YN. Side effects of antiepileptics - a review. Pain Practice 2004; 4: 194-203. Go to original source... Go to PubMed...
  17. Raspall-Chaure M, Neuville BG, Scott RC. The medical management of the epilepsies in children: conceptual and practical considerations. Lancet Neurol 2008; 7: 57-69. Go to original source... Go to PubMed...
  18. Shechter T, Shorer Z, Kramer U, et al. Adverse reactions of topiramate and lamotrigine in children. Pharmacoepidemiol Drug Saf 2005; 14: 187-192. Go to original source... Go to PubMed...
  19. Krauss GL. Evaluating risks for vigabatrin treatment. Epilepsy Currents 2009; 9: 125-129. Go to original source... Go to PubMed...
  20. Benavente-Aguilar I, Morales-Blánquez C, Rubio EA, Rey J. Quality of life of adolescents suffering from epilepsy living in the community. Child Care Health Dev 2004; 40: 110-113. Go to original source... Go to PubMed...
  21. Baker GA, Hargis E, Marshall MSH, Mounfield H, Arzimanoglou A. Perceived impact of epilepsy in teenagers and young adults: An international survey. Epilepsy Behav 2008; 12: 395-401. Go to original source... Go to PubMed...
  22. Räty LKA, Larsson BMW. Quality of life in young adults with uncomplicated epilepsy. Epilepsy Behav 2007; 10: 142-147. Go to original source... Go to PubMed...
  23. Montanaro M, Battistella P, Boniver C, Galeone D. Quality of life in young Italian patients with epilepsy. Ital J Neur Sci 2004; 25: 264-274. Go to original source... Go to PubMed...
  24. Baker GA, Spector S, McGrath Y, Soteriou H. Impact of epilepsy in adolescence: A UK controlled study. Epi Behav 2005; 6: 556-562. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.